Researchers have designed a bioresorbable implant that regenerates esophageal tissue after cancer surgery. The device aims to ...
Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for ...
FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit ...
New research has uncovered new insights into why the most aggressive esophageal cancers are so difficult to treat and how the ...
Esophageal cancer occurring in patients with head and neck squamous cell carcinoma (HNSCC) represents a critical clinical challenge, as these secondary tumours notably worsen patient prognosis. Owing ...
Please provide your email address to receive an email when new articles are posted on . Among patients with achalasia, esophageal Candida infection was independently associated with increased ...
US FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx, as companion diagnostic to aid in identifying patients with esophageal or GEJ carcinoma: Santa Clara, California Saturday, Marc ...
Approximately 600 times a day, the esophagus ferries whatever is in your mouth down to your stomach. It’s usually a one-way route, but sometimes acid escapes the stomach and travels back up. That can ...
FAIRFAX, Va. — Longtime Virginia Rep. Gerry Connolly passed away Wednesday morning following a battle with esophageal cancer. His family said in a statement that he passed away peacefully surrounded ...
Esophageal cancer is relatively rare, making up only 1% of all cancer diagnoses in the US. However, it is also one of the most deadly cancers — with a five-year survival rate of only 20%.
Eosinophilic esophagitis (EoE) is not associated with the development of esophageal cancer in privately insured US adults younger than 65 years. Because chronic inflammation is associated with several ...
The Augusta Fire Department partnered with Lucid Diagnostics to support firefighters’ health in relation to Esophageal Cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results